Date
29 August 2023
Further Pressure on Pharma Needed to Tackle AMR Risks
Chris Hall, writing for ESG Investor, takes an in-depth look at the Foundation's report on AMR and responsible antibiotic manufacturing. The article highlights how investors can get involved and help curb this global health threat.
Direct links
Suzi van Es, the Foundation's Investor Engagement Manager, is quoted: “Investors can make it clear to their investee companies they see AMR as a financially material risk in the pharmaceutical sector as well as a systemic risk to the global economy, and they can seek assurance these risks are managed effectively.”
The article picks up from the report that pharmaceutical companies are 'uniquely positioned to drive change' and can influence the whole supply chain to work to specific standards.